Uloric Lawsuits For Cardiovascular Deaths, Heart Problems, Strokes
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Uloric (febuxostat), prescribed for the management of chronic gout since 2009, has been associated with increased risk of cardiovascular deaths, heart problems, and strokes. In turn, Uloric lawsuits have been filed against Takeda Pharmaceuticals, the manufacturer of Uloric, alleging this drug company failed to adequately warn doctors and patients about these Uloric side effects.
Drug safety observers, such as the consumer advocacy group Public Citizen, contend that over time there is increasing evidence that the serious cardiovascular side effects of Uloric outweigh any purported clinical benefit from using this particular gout medicine.
Some serious Uloric side effects are:
- Cardiovascular Death (CV Death or CVD)
- Sudden Cardiac Arrest or Sudden Cardiac Death (SCD)
- Heart Failure (HF)
- Heart Attack or Myocardial Infarction (MI)
- Stroke or Cerebrovascular Accident (CVA)
- Unstable Angina with Urgent Coronary Revascularization
In February 2019 the FDA required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, for the Uloric drug label in order to better inform doctors and patients about the increased risks of heart-related deaths as well as deaths from all causes associated with the use of Uloric.
Our law firm is investigating possible Uloric lawsuits where patients have suffered cardiovascular Uloric side effects as personal injury cases or wrongful death claims, depending on the outcome.
We encourage you to submit a Uloric Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Uloric
Following recent FDA-mandated label changes, there have been Uloric lawsuits filed against Takeda Pharmaceuticals America, Inc., the manufacturer of Uloric.
Uloric (febuxostat) tablets have been generally prescribed for the management of chronic gout since 2009.
In February 2019 the FDA required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, for the Uloric drug label to inform about the increased risk of heart-related death and death from all causes with Uloric.
Further, the FDA required Takeda to make the following label changes:
To read more of this article, click below:
- Modify the “Indications and Usage” part of their Uloric drug label; and,
- Add a new section (5.1) titled “Cardiovascular Death” to the “Warnings and Precautions” part of their Uloric drug label, which includes this language:
Physicians and patients should remain alert for the development of adverse [cardiovascular (CV)] event signs and symptoms. Patients should be informed about the symptoms of serious [cardiovascular (CV)] events and the steps to take if they occur.
Our law firm is investigating possible Uloric lawsuits for patients who have suffered cardiovascular side effects such as strokes or heart attacks while taking Uloric. If we can be of assistance to you or someone else as regards a personal injury or wrongful death case, you can submit an online Uloric Case Evaluation Form or call us toll-free: 800-426-9535.[Read the article in full at original source]
Earlier articles about Uloric by attorney Tom Lamb on the Side Effects Blog:
- February 2019: Uloric “Black-Box Warning” For Heart-Related Deaths, Cardiovascular Side Effects
- Uloric Recall Discussed By FDA Advisory Committees In January 2019
- Will FDA Order Uloric Recall Requested In June 2018 By Public Citizen
- Gout Drug Uloric Has Higher Risk Of Death vs. Allopurinol: CARES Trial
- November 2017 FDA Alert: Uloric May Increase Heart-Related Deaths Risk